A crew of scientists at the Atal Incubation Centre (AIC) at CSIR-Centre for Cellular and Molecular Biology (CCMB), Hyderabad, has indigenously developed a potential mRNA vaccine candidate towards SARS-CoV-2. 

“The present warfare with Covid-19 had dropped at gentle many vaccine applied sciences and India’s vaccine programme is very lauded. However, we lacked the potent mRNA vaccine know-how, as developed by Moderna or Pfizer/BioNtech to fight Covid-19 within the US and Europe,’‘ Madhusudhana Rao, CEO, AIC-CCMB, and the lead scientist of the undertaking, informed newspersons right here on Friday. 

The know-how developed by AIC-CCMB is totally different from the mRNA vaccine being developed by Gennova Bio which is predicated on self-replicating RNA, Rao added. 

Proof-of-principle

The AIC-CCMB crew had been capable of set up mRNA vaccine know-how and develop a home-grown mRNA vaccine candidate towards SARS-CoV-2 in lower than a yr because the inception of the undertaking.

“Even though Covid-19 is waning, the vaccine platform holds promise for many infectious diseases that India faces,’‘ Rao said. 

“This a proof-of-principle wherein we have shown that we can replicate the mRNA vaccine technology end-to-end. The beauty of this technology is in its modularity and rapid turn-around times. That means that with significantly less efforts, the developed technology can be used to sire vaccines for other infectious diseases like dengue, tuberculosis or malaria,” mentioned Vinay Nandicoori, Director, CCMB.

CSIR, the most important analysis and growth organisation within the Ministry of Science and Technology, India, has taken prescient initiatives to ascertain capacities inside India in fashionable well being applied sciences as a part of its program on self-reliance, he added.

Pre-clinical problem research

Rajesh Iyer, a scientist concerned within the undertaking at AIC-CCMB, mentioned, “We observed robust immune responses against SARS-CoV-2 Spike protein in mice upon administration of two doses of the mRNA. The anti-spike antibodies generated were found to be more than 90 per cent efficient in preventing the human ACE2 receptor binding to the coronavirus.” 

mRNA vaccine know-how does this by introducing an mRNA of the micro-organism of concern. This mRNA within the host cells provides rise to the microbial protein, or part of it, which trains the immune system to evade an infection when it occurs with the identical reside micro-organism. 

Currently, the vaccine candidate of CCMB is present process pre-clinical problem research to consider its efficacy to guard towards reside virus an infection.

Published on

May 13, 2022



Sources

Leave a Reply

Your email address will not be published.